Health Canada Approves First Low Dose Treatment Option to Help Women Better Manage Menopause



    ~ The Lowdown on menopause: More than 90 per cent of women aged 40 to 60
    won't let symptoms get in the way of life(1) ~

    MISSISSAUGA, ON, June 17 /CNW/ - Ninety per cent of Canadian women aged
40 to 60 feel that managing symptoms associated with menopause is important,
according to a recent survey; however, 40 per cent have done nothing to manage
their symptoms(2). Commonly reported symptoms including hot flushes, sleep
disturbance and irritability/depression can affect daily functioning and
quality of life at a time when women are more likely to feel empowered and
excited about this new stage of life. Health Canada has approved Activelle(R)
LD (Estradiol / Norethindrone Acetate), the first low dose (combination
estrogen and progestogen) hormone therapy (HT) to provide effective relief of
hot flushes related to menopause, in one convenient tablet.
    "Today's women entering menopause don't want their symptoms to slow them
down; however, there has been a reluctance in the past for women to manage
their symptoms using hormone therapy due to perceived risks," said Wendy
Wolfman, Associate Professor of Obstetrics and Gynaecology at the University
of Toronto, and Director of the Menopause Unit at Mount Sinai Hospital. "New
low dose treatment options with minimal side effects can effectively address
symptoms related to menopause, and allow women to take control of their
health."
    The use of the lowest effective HT dose for the treatment of
menopause-related symptoms is recommended by expert associations and
clinicians, including the Society of Obstetricians and Gynaecologists of
Canada (SOGC) and the North American Menopause Society (NAMS). According to
recent recommendations by the International Menopause Society (IMS), HT is
considered the gold standard treatment for moderate to severe menopausal
symptoms, and should be considered the first treatment option, in the absence
of any contraindications.(3)"
    "Hormone therapy should be prescribed at the lowest effective dose to
achieve relief of symptoms associated with menopause," said Dr. Guylaine
Lefebvre, President of the Society of Obstetricians and Gynaecologists of
Canada. The SOGC, one of the nation's leading authorities on women's health,
supports Health Canada's decision. "We are pleased that there is a new option
available to Canadian women. With that, it is important that women speak with
their physician to determine if hormone therapy is an option for them."
    "We know so much more about hormone therapy than we did in 2002 when the
Women's Health Initiative raised concerns about the health effects of hormone
therapy," said Dr. Robert Reid, Professor of Obstetrics and Gynaecology and
Chair of the Division of Reproductive Endocrinology and Infertility at Queen's
University. "Activelle LD provides the lowest effective combined estrogen and
progestogen dose available in Canada, making it a new option both for women
who are beginning hormone therapy, as well as for women looking to 'step down'
to a lower dose."

    Menopause and Today's Women Survey: Key Highlights

    
    -   Forty per cent of those who have experienced symptoms have not done
        anything to manage these symptoms; however, the vast majority (91 per
        cent) said that they feel it is important to do so
    -   Fifty-nine per cent of women aged 40 to 60 have started experiencing
        or have been through menopause, and 64 per cent (even some who say
        menopause has not started yet for them) have experienced at least
        some symptoms
    -   Most women who have experienced symptoms associated with menopause
        have experienced physical symptoms (94 per cent) with hot flushes /
        night sweats (84 per cent) being the most common
    -   More than one-third (39 per cent) have experienced emotional symptoms
        including mood swings, irritability and/or depression
    -   While the majority of women are concerned that all symptoms of
        menopause will impact their life, difficulty concentrating causes the
        most concern (70 per cent)
    -   Fifty-four percent of women say they would be likely to consider a
        lower dose of HT if it comes with a recommendation from the SOGC
    

    About Activelle(R) LD

    Health Canada's approval of Activelle LD was based in part on the
findings from the Choice Study (Clinical Study on Hormone Dose Optimisation In
C limacteric Symptom Evaluation), a six month double-blind, randomized,
parallel-group, placebo-controlled, multi-centre trial to investigate the
efficacy and safety of an ultra-low dose combination with 0.5 mg estradiol and
0.1 mg norethindrone acetate for treatment of menopausal symptoms.
    The study found that Activelle LD produced a rapid and significant
reduction in the frequency (70.9/week to 13.2/week, p (less than or equal to)
0.001) and severity (mean change in severity score of 9.1, p(equals)0.001) of
moderate to severe hot flushes associated with menopause, and improvement in
the Greene Climacteric Scale Score, as compared with placebo (mean total
symptoms score from 18 to 8, p (equals)0.001).
    The study also demonstrated tolerability and minimal side effects in the
majority of patients. Clinically important symptoms related to the breast
(breast discomfort, breast pain and tenderness) were reported by only three
per cent of actively treated women, which was the same percentage as in the
placebo group.

    About Menopause

    In Canada, women spend more than one-third of their lives in the
postmenopausal era. Menopause is the permanent cessation of menstruation,
which occurs when the ovaries no longer release an egg each month and
therefore cease to produce the female sex hormones estrogen and progestogen.
Menopause generally begins between the age of 48 and 52. It can also occur if
a woman has had surgery to remove her ovaries or if chemotherapy, radiotherapy
or HT causes ovarian failure. The post-menopausal period and its associated
symptoms can last up to 15 years, depending on the individual.
    Women in menopause have an increased risk of developing osteoporosis.
During the first five years after menopause, three to five per cent of a
woman's bone mass is lost each year, and an additional one to two per cent is
lost each year following.

    About Novo Nordisk Canada Inc.

    Novo Nordisk is a healthcare company and a world leader in diabetes care
and biopharmaceuticals. Novo Nordisk manufactures and markets pharmaceutical
products and services that make a significant difference to patients, the
medical profession and society. Novo Nordisk's business is driven by the
Triple Bottom Line: a commitment to economic success, environmental soundness,
and social responsibility to employees and customers. For more information,
visit www.novonordisk.ca.

    
    ----------------------------
    References:
    (1) Leger Marketing. Menopause and Today's Women. Online study of 800
        Canadian women ages 40-60 living across the country. Surveys were
        conducted between May 15th and May 21st, 2008.
    (2) Ibid.
    (3) Birkhauser MH, Panay N, Archer DF, et al. Updated practical
        recommendations for hormone replacement therapy in the peri- and
        postmenopause. Climacteric 2008;1(1):108-123.
    





For further information:

For further information: Laura Grice, Manning Selvage & Lee (MS&L),
(416) 847-1319, laura.grice@mslpr.ca


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890